Immunovant stakes claim for FcRn niche, posting midphase Graves’ data and plotting next steps

Immunovant has advanced its mission to claim an unoccupied area of the competitive anti-FcRn space, reporting phase 2 data that support its attempt to be the first to market in Graves’ disease.